Tuesday, 19 August 2003
This presentation is part of : Subtypes of Dementia

S031-001 Lewy Body Dementia in a Nursing Home Population: Specificity and Sensitivity of the McKeith Diagnostic Criteria, the Rate of Progression of Symptoms, and Side Effects of Neuroleptic Therapy

Albert Wettstein, Center of Gerontology, University of Zurich, Zurich, Switzerland, Christian Strübi, City Medical Service, Zurich, Switzerland, and David Nochlin, University of Washington Medical School, Department Neuropathology, Seattle, WA, USA.

Design: 308 nursing home patients were prospectively evaluated every 6 months from 1987-93 (diagnosis, mini mental status MMS, ADL score, involuntary events and extrapyramidal symptom scale, and prescription of neuroleptics).

Materials and Methods: Of these, 137 had a brain autopsy performed and an immunohistochemical examination of temporal, parietal, and frontal cortex, according to the consensus criteria of the McKeith criteria for Lewy Body Dementia (LBD). The clinical diagnostic criteria were used for a retrospective chart analysis by a geriatrician blind to the histopathological results.

Results: 16 of the 111 patients with dementia had a pathological diagnosis of LBD. The McKeith clinical diagnostic criteria showed a sensitivity of 0.38 and a specificity of 0.93. The rate of cognitive deterioration was highest in cases with LBD (-4.7 pt in MMS/6months) in comparison to patients with Alzheimer's disease (-1.6 pt/6months) or other dementias (-1.3 pt/6months). The extrapyramidal symptoms showed only moderate deterioration in LBD but moderate to severe worsening in most Alzheimer’s patients.

Conclusion: Patients with LBD had the highest average neuroleptic doses (38 mg chlorpromazine equivalents/d for LBD and 22 mg for Alzheimer dementia). Men with neuroleptics and LBD had a dose-dependent shortening of survival, which was not observed in women.

Back to S031 Subtypes of Dementia
Back to The Eleventh International Congress